atacand plus mite 8 mg / 12.5 mg
cheplapharm arzneimittel gmbh - kandesartancileksetil / hydroklortiazid - tablett - 8 mg / 12.5 mg
atacand plus 32 mg / 12.5 mg
cheplapharm arzneimittel gmbh - kandesartancileksetil / hydroklortiazid - tablett - 32 mg / 12.5 mg
candesartan/hydrochlorothiazide orion 8 mg / 12.5 mg
orion corporation - espoo - kandesartancileksetil / hydroklortiazid - tablett - 8 mg / 12.5 mg
candesartan/hydrochlorothiazide orion 16 mg / 12.5 mg
orion corporation - espoo - kandesartancileksetil / hydroklortiazid - tablett - 16 mg / 12.5 mg
paroxetin actavis 20 mg
actavis group ptc ehf (1) - paroksetinhydroklorid - tablett, filmdrasjert - 20 mg
crysvita
kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - legemidler til behandling av bein sykdommer - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.
methylphenidate teva 60 mg
teva b.v. - metylfenidathydroklorid - kapsel med modifisert frisetting, hard - 60 mg
methylphenidate teva 10 mg
teva b.v. - metylfenidathydroklorid - kapsel med modifisert frisetting, hard - 10 mg
methylphenidate teva 20 mg
teva b.v. - metylfenidathydroklorid - kapsel med modifisert frisetting, hard - 20 mg
methylphenidate teva 30 mg
teva b.v. - metylfenidathydroklorid - kapsel med modifisert frisetting, hard - 30 mg